Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer
Bionure, a biotech company specialized in neuroprotection, today announces that it has appointed Dr. Lucia Septien as chief medical officer.
Immunocore has appointed Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer. Mohammed Dar will lead the continued clinical development of tebentafusp(IMCgp100) and other key programmes in Immunocore’s pipeline.
Medica Group Plc (LSE:MGP) announces that Dr Stuart Quin has been appointed as Chief Executive Officer. Dr Quin will join Medica and its Board of Directors on 1 September 2019. John Graham will remain as Chief Executive Officer until Dr Quin joins the company.
Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries.
Medica Group Plc (LSE:MGP) announces that Jo Easton has been appointed to the Group’s Board of Directors as a non-executive director. On joining the Board, Jo will be appointed to the audit, nomination and remuneration committees.
IGEM Therapeutics, an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announces that Dr David Chiswell will be joining IGEM as a Non-Executive Chairman effective immediately.
Metrion Biosciences today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer.
Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Theodora Harold, the current CFO, will be appointed as CEO. She will be succeeding Peter Pack who will be stepping down from the position of CEO on 1 May 2019.
Ergomed plc, a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Roy Ovel as Chief Commercial Officer with immediate effect.